World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
102
Citations
44215
World Ranking
367
National Ranking
168

Medicine

D-Index
102
Citations
44273
World Ranking
7580
National Ranking
3952

Michael J. Rybak publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Michael J. Rybak sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 478 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Michael J. Rybak D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. Rybak sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 102 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Michael J. Rybak is affiliated with Wayne State University in the United States and has a significant research output focused primarily on infectious diseases and pharmacology within the broader fields of medicine and biochemistry, genetics, and molecular biology. Their work spans 174 publications in medicine and 90 in biochemistry, genetics, and molecular biology.

Their research concentrates on subfields including infectious diseases, pharmacology, molecular medicine, epidemiology, and clinical biochemistry. Main topics covered in their studies include antimicrobial resistance in Staphylococcus, antibiotic resistance in bacteria, antibiotics pharmacokinetics and efficacy, bacterial identification and susceptibility testing, antibiotic use and resistance, bacteriophages and microbial interactions, and microbial infections and disease research.

Notable recent papers by Michael J. Rybak include the following:

  • Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists (2020), published in American Journal of Health-System Pharmacy
  • Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists (2020), published in Clinical Infectious Diseases
  • Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists (2020), published in Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Frequent coauthors collaborating with Michael J. Rybak include:

  • Taylor Morrisette
  • Razieh Kebriaei
  • Sara Alosaimy
  • Ashlan J. Kunz Coyne
  • Abdalhamid M Lagnf

Their publications have appeared most often in the following venues:

  • Open Forum Infectious Diseases
  • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  • Antimicrobial Agents and Chemotherapy
  • Microbiology Spectrum
  • Antibiotics

Best Publications

  • Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

    Catherine Liu;Arnold Bayer;Sara E. Cosgrove;Robert S. Daum

  • Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association

    Larry M. Baddour;Walter R. Wilson;Arnold S. Bayer;Vance G. Fowler

  • Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

    Michael Rybak;Joseph R. Dalovisio

  • Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

    Michael J Rybak;Michael J Rybak;Michael J Rybak;Jennifer Le;Thomas P Lodise;Donald P Levine;Donald P Levine

  • Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

    Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering

  • The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin

    Michael J. Rybak

  • Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia

    Thomas P. Lodise;Peggy S. McKinnon;Linda Swiderski;Michael J. Rybak

  • Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets

    Ravina Kullar;Susan L. Davis;Susan L. Davis;Donald P. Levine;Michael J. Rybak;Michael J. Rybak

  • Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

    Michael J. Rybak;Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering

  • Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity

    Michael J. Rybak;Michael J. Rybak;Betty J. Abate;S. Lena Kang;Michael J. Ruffing

  • In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

    Michael J. Rybak;Ellie Hershberger;Tabitha Moldovan;Richard G. Grucz

  • Nephrotoxicity of vancomycin, alone and with an aminoglycoside

    Michael J. Rybak;Lisa M. Albrecht;Steven C. Boike;Pranatharthi H. Chandrasekar

  • Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model

    Kerry L. LaPlante;Michael J. Rybak;Michael J. Rybak

  • Pharmacodynamics of cefepime in patients with Gram-negative infections

    Vincent H. Tam;Peggy S. McKinnon;Ronda L. Akins;Michael J. Rybak

  • The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

    Robert W. Finberg;Robert C. Moellering;Francis P. Tally;William A. Craig

  • Ceragenins: cholic acid-based mimics of antimicrobial peptides.

    Xin Zhong Lai;Yanshu Feng;Jacob Pollard;Judy N. Chin

  • Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

    Ronda L. Akins;Michael J. Rybak;Michael J. Rybak

  • A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

    Natalie A. Finch;Evan J. Zasowski;Kyle P. Murray;Ryan P. Mynatt

  • Tigecycline: first of a new class of antimicrobial agents.

    Warren E. Rose;Michael J. Rybak;Michael J. Rybak;Michael J. Rybak

  • The β-Lactams Strike Back: Ceftazidime-Avibactam.

    Evan J. Zasowski;Jeffrey M. Rybak;Michael J. Rybak;Michael J. Rybak;Michael J. Rybak

  • Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

    A S Benko;D M Cappelletty;J A Kruse;M J Rybak

  • Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study

    Kyle P. Murray;Jing J. Zhao;Susan L. Davis;Ravina Kullar

Frequent Co-Authors

George Sakoulas
George Sakoulas University of California, San Diego
Glenn W. Kaatz
Glenn W. Kaatz Wayne State University
Jason M. Pogue
Jason M. Pogue University of Michigan–Ann Arbor
Cesar A. Arias
Cesar A. Arias The University of Texas Health Science Center at Houston
Keith S. Kaye
Keith S. Kaye Rutgers, The State University of New Jersey
Brian T. Tsuji
Brian T. Tsuji University at Buffalo, State University of New York
Emily T. Martin
Emily T. Martin University of Michigan–Ann Arbor
Ronald N. Jones
Ronald N. Jones JMI Laboratories
Thomas P. Lodise
Thomas P. Lodise Albany College of Pharmacy and Health Sciences
Arnold S. Bayer
Arnold S. Bayer University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers related to Microbiology often leads to diverse opportunities in healthcare, research, and specialized fields. For example, becoming a certified child life specialist salary is attractive for those interested in supporting children's emotional well-being during medical treatments.

Individuals with unique backgrounds may find hope in programs highlighted under degrees felons can get. Such online degrees open doors for felons seeking a fresh start in scientific or healthcare professions.

Healthcare-focused careers like a Functional Medicine Nurse Practitioner are increasingly popular. Insights about functional medicine nurse practitioner salary demonstrate the potential financial rewards and growing demand in this specialized field.

For those interested in the administrative side of healthcare, earning a Certified Professional Coder credential offers a practical pathway. Understanding the cpc certification salary and career paths reveals a steady profession supporting medical billing and coding processes.

Best Scientists Citing Michael J. Rybak

Trending Scientists

Recently Published Articles